A Study of MK-0616 (Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017) CORALreef HeFH
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05952869 |
Recruitment Status :
Active, not recruiting
First Posted : July 19, 2023
Last Update Posted : March 13, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hypercholesterolemia Familial Hypercholesterolemia | Drug: MK-0616 Drug: Placebo | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 270 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Heterozygous Familial Hypercholesterolemia |
Actual Study Start Date : | August 8, 2023 |
Estimated Primary Completion Date : | April 28, 2025 |
Estimated Study Completion Date : | April 28, 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: MK-0616
Participants will receive 20 mg of MK-0616 orally once daily (QD) for up to 52 weeks.
|
Drug: MK-0616
Oral tablet |
Placebo Comparator: Placebo
Participants will receive MK-0616-matching placebo orally QD for up to 52 weeks.
|
Drug: Placebo
Placebo |
- Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 24 [ Time Frame: Baseline and Week 24 ]Blood samples will be collected at baseline and at Week 24 to assess mean percent change in LDL-C.
- Number of participants with one or more adverse events (AEs) [ Time Frame: Up to ~60 weeks ]An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
- Number of participants who discontinue study drug due to an AE [ Time Frame: Up to ~52 weeks ]An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
- Mean percent change from baseline in LDL-C at Week 52 [ Time Frame: Baseline and Week 52 ]Blood samples will be collected at baseline and at Week 52 to assess mean percent change in LDL-C.
- Mean percent change from baseline in non-high-density lipoprotein cholesterol (HDL-C) at Week 24 [ Time Frame: Baseline and Week 24 ]Blood samples will be collected at baseline and at Week 24 to assess mean percent change in non-HDL-C.
- Mean percent change from baseline in apolipoprotein B (ApoB) at Week 24 [ Time Frame: Baseline and Week 24 ]Blood samples will be collected at baseline and at Week 24 to assess mean percent change in ApoB.
- Percent change from baseline in lipoprotein(a) (Lp[a]) at Week 24 [ Time Frame: Baseline and Week 24 ]Blood samples will be collected at baseline and at Week 24 to assess percent change in Lp(a).
- Percentage of participants with LDL-C <70 mg/dL and ≥50% reduction from baseline at Week 24 [ Time Frame: Baseline and Week 24 ]Blood samples will be collected at baseline and at Week 24 to assess the percentage of participants who have LDL-C <70 mg/dL and ≥50% reduction from baseline.
- Percentage of participants with LDL-C <55 mg/dL and ≥50% reduction from baseline at Week 24 [ Time Frame: Baseline and Week 24 ]Blood samples will be collected at baseline and at Week 24 to assess the percentage of participants who have LDL-C <55 mg/dL and ≥50% reduction from baseline.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Has possible or definite diagnosis of heterozygous familial hypercholesterolemia (HeFH) based on a locally accepted diagnostic algorithm
- Has an LDL-C ≥55 mg/dL or ≥70 mg/dL depending on medical history
- Is treated with a moderate- or high-intensity statin medication
- Is on a stable dose of all background lipid-lowering therapies (LLTs) with no planned medication change
Exclusion Criteria:
- Has a history of homozygous familial hypercholesterolemia (FH) based on genetic or clinical criteria, compound heterozygous FH, or double heterozygous FH
- Has a history of heart failure or heart failure hospitalization within 3 months before first study visit
- Is undergoing or previously underwent an LDL-C apheresis program within 3 months before first study visit or plans to initiate an LDL-C apheresis program
- Was previously treated/is being treated with certain other cholesterol lowering medications, including protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05952869
Study Director: | Medical Director | Merck Sharp & Dohme LLC |
Responsible Party: | Merck Sharp & Dohme LLC |
ClinicalTrials.gov Identifier: | NCT05952869 |
Other Study ID Numbers: |
0616-017 MK-0616-017 ( Other Identifier: Merck ) 2022-502782-14 ( Registry Identifier: EU CT ) U1111-1285-4257 ( Other Identifier: UTN ) |
First Posted: | July 19, 2023 Key Record Dates |
Last Update Posted: | March 13, 2024 |
Last Verified: | March 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf |
URL: | http://engagezone.msd.com/ds_documentation.php |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Hyperlipoproteinemia Type II Hypercholesterolemia Hyperlipidemias Dyslipidemias Lipid Metabolism Disorders |
Metabolic Diseases Lipid Metabolism, Inborn Errors Metabolism, Inborn Errors Genetic Diseases, Inborn Hyperlipoproteinemias |